BioAge Labs, a California-based biotech company, is making strides in the field of metabolic aging by harnessing the power of machine learning. According to the results published in the material, their innovative approach involves a collaboration with Norwegian diagnostics firm Age Labs AS and the HUNT Biobank to analyze extensive health data.
Partnership Overview
The partnership aims to filter and interpret long-term health data, which could provide valuable insights into the aging process and its metabolic implications. BioAge Labs is focused on advancing its research and is set to complete its Phase 1 study on the NLRP3 inhibitor BGE102 by the second half of 2026.
Clinical Trials and Research Focus
In addition to the NLRP3 inhibitor, the company is also working on clinical trials for treatments that target metabolic disorders and strategies for weight loss. This multifaceted approach highlights BioAge's commitment to addressing significant health challenges associated with aging. It potentially paves the way for new therapeutic options.
The recent Phase 3 PEAK trial results have shown significant efficacy for Bezuclastinib in cancer treatment, contrasting with BioAge Labs' focus on metabolic aging research. For more details, see read more.
